Key result
Atrasentan-associated fluid retention is predicted by higher dose, lower eGFR, higher HbA1c, and higher systolic BP.
Why the study?
Endothelin A receptor antagonists reduce albuminuria in diabetic kidney disease but their use may be limited by fluid retention, necessitating identification of predictors for ERA-induced fluid retention.
What are the predictors of atrasentan-induced fluid retention, and does fluid retention correlate with albuminuria reduction in patients with type 2 diabetes and CKD?
RCT (n=211)
randomly assigned
Yes
What are the predictors of atrasentan-induced fluid retention, and does fluid retention correlate with albuminuria reduction in patients with type 2 diabetes and CKD?
Atrasentan-associated fluid retention in diabetic nephropathy is predicted by lower eGFR and higher dose, but does not impair its albuminuria-reducing efficacy.
Answers are grounded in this paper and cite their sources.
May inform risk stratification for atrasentan fluid retention in diabetic CKD; leaves open prospective validation in randomized trials.
BACKGROUND AND OBJECTIVES: Endothelin A receptor antagonists (ERAs) decrease residual albuminuria in patients with diabetic kidney disease; however, their clinical utility may be limited by fluid retention. Consequently, the primary objective of this study was to identify predictors for ERA-induced fluid retention among patients with type 2 diabetes and CKD. A secondary objective was to determine if the degree of fluid retention necessarily correlated with the magnitude of albuminuria reduction in those patients receiving ERAs. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: A post hoc analysis was conducted of the phase IIb atrasentan trials assessing albuminuria reduction in 211 patients with type 2 diabetes, urine albumin/creatinine ratios of 300-3500 mg/g, and eGFRs of 30-75 ml/min per 1.73 m(2) who were randomly assigned to receive placebo (n=50) or atrasentan 0.75 mg/d (n=78) or 1.25 mg/d (n=83) for 12 weeks. Changes in body weight and hemoglobin (Hb) after 2 weeks of treatment were used as surrogate markers of fluid retention. RESULTS: Baseline predictors of weight gain after 2 weeks of atrasentan treatment were higher atrasentan dose, lower eGFR, higher glycated hemoglobin, higher systolic BP, and lower homeostatic metabolic assessment product. Higher atrasentan dose and lower eGFR also predicted decreases in Hb. There were no changes in B-type natriuretic peptide. There was no correlation between reduction in albuminuria after 2 weeks of atrasentan treatment and changes in body weight or Hb. CONCLUSIONS: In the Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan/JAPAN trials, atrasentan-associated fluid retention was more likely in patients with diabetes and nephropathy who had lower eGFR or received a higher dose of atrasentan. Finding that albuminuria reduction was not associated with changes in body weight and Hb suggests that the albuminuria-reducing efficacy of atrasentan is not impaired by fluid retention.
No takes yet. Share an insight, caveat, or question.
Kohan et al. (2015) conducted an RCT in Type 2 diabetes and CKD (diabetic nephropathy) (n=211). Atrasentan vs. Placebo was evaluated on Predictors of fluid retention (changes in body weight and hemoglobin after 2 weeks). Atrasentan-associated fluid retention was predicted by higher dose, lower eGFR, higher HbA1c, and higher systolic BP, but did not correlate with the magnitude of albuminuria reduction.
Synapse has enriched 10 related papers. Consider them for comparative context: